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Abstract
Background: There is no international consensus up to which age women with a diagnosis of triple-negative
breast cancer (TNBC) and no family history of breast or ovarian cancer should be offered genetic testing for
germline BRCA1 and BRCA2 (gBRCA) mutations. Here, we explored the association of age at TNBC diagnosis with
the prevalence of pathogenic gBRCA mutations in this patient group.
Methods: The study comprised 802 women (median age 40 years, range 19–76) with oestrogen receptor,
progesterone receptor, and human epidermal growth factor receptor type 2 negative breast cancers, who had no
relatives with breast or ovarian cancer. All women were tested for pathogenic gBRCA mutations. Logistic regression
analysis was used to explore the association between age at TNBC diagnosis and the presence of a pathogenic
gBRCA mutation.
Results: A total of 127 women with TNBC (15.8%) were gBRCA mutation carriers (BRCA1: n = 118, 14.7%; BRCA2: n = 9, 1.
1%). The mutation prevalence was 32.9% in the age group 20–29 years compared to 6.9% in the age group 60–69 years.
Logistic regression analysis revealed a significant increase of mutation frequency with decreasing age at diagnosis (odds
ratio 1.87 per 10 year decrease, 95%CI 1.50–2.32, p < 0.001). gBRCA mutation risk was predicted to be > 10% for women
diagnosed below approximately 50 years.
Conclusions: Based on the general understanding that a heterozygous mutation probability of 10% or greater justifies
gBRCA mutation screening, women with TNBC diagnosed before the age of 50 years and no familial history of breast and
ovarian cancer should be tested for gBRCA mutations. In Germany, this would concern approximately 880 women with
newly diagnosed TNBC per year, of whom approximately 150 are expected to be identified as carriers of a pathogenic
gBRCA mutation.
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Background
Triple-negative breast cancer (TNBC) is characterized
by lacking expression of oestrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth
factor receptor type 2 (HER2). TNBC has been reported
to account for 12–24% of all breast cancers and is asso-
ciated with a hereditary disease cause [1–3]. While
germline BRCA1/2 (gBRCA) mutations are found in
about 5% of all breast cancers, higher mutation rates are
observed in TNBC patients depending on age of onset
and the presence of a family history of breast and ovar-
ian cancer [4]. Approximately 70% of breast cancers
arising in BRCA1 mutation carriers and up to 23% of
breast cancers in BRCA2 carriers are triple-negative [2].
Consequently, some guidelines suggest genetic gBRCA
mutation testing in this particular group of patients. For
example, the National Institute for Health and Care Ex-
cellence (NICE) guidelines recommend gBRCA testing if
the combined BRCA1 and BRCA2 mutation carrier
probability is expected to be at least 10% [5]. According
to the National Comprehensive Cancer Network (NCCN)
and the American Society of Breast Surgeons, gBRCA
testing is generally advised for women with TNBC di-
agnosed at an age of ≤60 years, irrespective of a positive
cancer family history.
It is less clear, however, up to which age at TNBC
diagnosis women, who do not have a family history of
breast and ovarian cancer, should be recommended gen-
etic testing. This prompted us to determine the age-
dependent prevalence of gBRCA mutations in women
with unilateral TNBC and without any family history of
breast or ovarian cancer.
Methods
Study population
The study population comprised a total of 802 women with
TNBC, who reported not to have any relatives with breast
or ovarian cancer in their families. Of these, 649 women
were consecutively registered and documented between
July 1999 and January 2016 in 15 specialized university cen-
tres of the German Consortium for Hereditary Breast and
Ovarian Cancer (GC-HBOC). GC-HBOC collects data on
families suspected of having hereditary breast and ovarian
cancer based on a defined set of clinical ascertainment cri-
teria [6]. At the time of data analysis, a total of 2029 women
with TNBC were recorded in the GC-HBOC registry (ie.,
1380 with and 649 without a family history of breast and
ovarian cancer). Women with a TNBC diagnosis before age
36, who did not have any familial cancer history, were in-
cluded since 1999, while women with a later TNBC diagno-
sis were collected mainly since 2011, resulting in some
overrepresentation of women with younger age at TNBC
diagnosis. Another 153 women were taken from the ran-
domized controlled GeparSixto (GBG 66, clinicaltrials.gov
identifier: NCT01426880) trial of the German Breast Group
(GBG) [7, 8]. These women were consecutively recruited
between August 2011 and December 2012. Women with
syn- or metachronous bilateral breast cancer and/or ovarian
cancer were excluded. Family history was collected and
documented by a medical health professional (geneticist,
genetic counselor, and/or gynecologist) after the diagnosis
of TNBC. Pedigree information was required to encompass
at least three generations.
The multicentre GC-HBOC registry and the multicentre
GBG GeparSixto trial have been approved by the respon-
sible ethics committees. Written informed consent to be
enrolled in the GC-HBOC registry or the GBG GeparSixto
trial, respectively, was obtained from all individuals whose
data was used for the present analysis.
Receptor status and mutation analysis
ER, PR and HER2 expression was determined according
to the national pathology guidelines of the ‘AGO Breast
Committee’, which adheres closely to international stan-
dards. Triple negativity was defined as immunohisto-
chemical staining of less than 1% of nuclei for both ER
and PR, and an immunhistochemical result (DAKO score)
of 0 or 1+ for Her2/neu. Mutation analyses were per-
formed using either next generation sequencing methods
or denaturing high-performance liquid chromatography
and high-resolution melting followed by direct Sanger-
based sequencing of conspicuous fragments [9, 10]. If no
deleterious sequence alterations were found in these ana-
lyses, samples were screened for large genomic alterations
in the BRCA1/2 genes by Multiplex Ligation-dependent
Probe Amplification (MLPA) with the SALSA® MLPA®
probemixes P002 for BRCA1 and P045 for BRCA2 (MRC-
Holland, Amsterdam, The Netherlands) according to the
manufacturer’s protocol. Mutations were classified accord-
ing to the International Agency for Research on Cancer
(IARC) system and considered pathogenic or likely patho-
genic (class 4 or 5) based on literature evidence, multifac-
torial likelihood and functional analyses of the ENIGMA
consortium that comprises genetic data of the GC-HBOC
database [11, 12].
Statistical analysis
Logistic regression was used to analyse the association be-
tween age of diagnosis and the presence of a gBRCA mu-
tation. Ninety-five percent confidence intervals for
frequencies were calculated applying Wilson’s score
method. For the calculation of the expected annual num-
ber of gBRCA mutation carriers among women with
TNBC and without any relatives with breast or ovarian
cancer, data on the age-specific annual numbers of all
breast cancers in Germany were obtained from pooled
data of the German Epidemiological Cancer Registries
(German Centre for Cancer Registry Data at the Robert
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Koch-Institute, Berlin, Germany). Age-specific frequencies
of TNBC cases among all breast cancers were kindly pro-
vided by the Munich Cancer Registry (MCR, Munich,
Germany). The age-specific proportions of TNBC without
a positive family history among unselected TNBC were
taken from Couch et al. [13]. P-values < 0.05 were consid-
ered significant. Statistical analyses were conducted using
IBM SPSS Statistics for Windows Version 23.0 (IBM Cor-
poration, Armonk, NY, USA) and R 3.3.2 for Windows (R
Core Team, www.r-project.org).
Results
A total of 802 patients were included in the study (649
from the GC-HBOC registry and 153 from the GBG
randomized controlled GeparSixto trial). Basic patient
characteristics are shown in Table 1. The median age at
TNBC diagnosis was 40 (range 19–76) years and the
overall prevalence of pathogenic gBRCA mutations was
15.8% (14.7% for BRCA1 and 1.1% for BRCA2). BRCA1
mutation carriers were younger at diagnosis (34 years)
than BRCA2 mutation carriers (47 years). Non-carriers
had a median age at diagnosis of 42 years. Patients from
the GeparSixto study were older at primary TNBC diag-
nosis compared to the patients from the GC-HBOC
registry (48 vs. 38 years), and had a lower mutation
prevalence (9.8% vs. 17.3%). The considerably lower age
at TNBC diagnosis of GC-HBOC patients is explained
by an overrepresentation of women diagnosed before the
age of 36 years (see Materials). Table 2 depicts the age-
group specific BRCA1 and BRCA2 mutation prevalence.
The mutation prevalence increased with younger age at
diagnosis. While in about one third of the very young
patients (20 to 29 years) a gBRCA mutation was de-
tected (33%), the prevalence was below 7% in older pa-
tients between 60 and 69 years.
To assess the association between age of TNBC at
diagnosis and gBRCA mutation prevalence, a logistic re-
gression analysis was performed (Fig. 1). This analysis
revealed a significant negative association between age at
diagnosis and the presence of a gBRCA mutation (OR
1.87 per 10 year decrease, 95%CI 1.50 to 2.32, p < 0.001).
At an age of approximately 48 years or younger, the pre-
dicted mutation probability was > 10%, which is the cur-
rently accepted international threshold to recommend
gBRCA testing according to the NICE guidelines [5].
The origin of the data (GC-HBOC registry versus GBG
GeparSixto trial) did not play a role as a significant con-
founder in the regression analysis (p = 0.823).
The performance of age at TNBC diagnosis to dis-
criminate between gBRCA carriers and non-carriers, as
characterized by the area under the curve of the
receiver-operating-characteristic (ROC-AUC), was 67.0%
(95%CI 62.1–71.9%). Recommendation of genetic testing
only to TNBC patients diagnosed before the age of
Table 1 Basic patient characteristics
Total n = 802 GC-HBOC n = 649 GBG n = 153
BRCA mutation status, no (%)
negative 675 (84.2) 537 (82.7) 138 (90.2)
BRCA1 118 (14.7) 107 (16.5) 11 (7.2)
BRCA2 9 (1.1) 5 (0.8) 4 (2.6)
Age at diagnosis, years (median, range) 40.1 (19.5–76.2) 38.0 (19.5–76.2) 48.0 (21.0–74.0)
negative 42.0 (19.5–76.2) 38.7 (19.5–76.2) 48.5 (26.0–74.0)
BRCA1 34.1 (21.0–63.5) 33.5 (25.0–63.5) 41.0 (21.0–61.0)
BRCA2 47.2 (34.3–63.1) 47.1 (34.3–63.1) 54.0 (39.0–63.0)
Table 2 BRCA 1/2 germline mutation prevalence by age group
n BRCA1 BRCA2 BRCA1/2
n % (95%CI) n % (95%CI) n % (95%CI)
Age group (years)
20–29 85 28 32.9 (23.9–43.5) 0 0.0 (0.0–4.3) 28 32.9 (23.9–43.5)
30–39 309 60 19.4 (15.4–24.2) 3 1.0 (0.3–2.8) 63 20.4 (16.3–25.2)
40–49 216 22 10.2 (6.8–14.9) 3 1.4 (0.5–4.0) 25 11.6 (8.0–16.5)
50–59 122 6 4.9 (2.3–10.3) 1 0.8 (0.1–4.5) 7 5.7 (2.8–11.4)
60–69 58 2 3.4 (1.0–11.7) 2 3.4 (1.0–11.7) 4 6.9 (2.7–16.4)
70–79 12 0 0.0 (0.0–24.2) 0 0.0 (0.0–24.2) 0 0.0 (0.0–24.2)
TOTAL 802 118 14.7 (12.4–17.3) 9 1.1 (0.6–2.1) 127 15.8 (13.5–18.5)
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50 years would result in a sensitivity of 96.9% (95%CI
92.2–98.8%) and a specificity of 9.8% (95%CI 7.8–12.3%).
Table 3 shows an estimation of the expected annual
number of TNBC cases with a gBRCA mutation in
the general German population, based on the age-
specific absolute numbers of all breast cancers up to
an age of 80 years and the expected rate of TNBC
cases without family history. According to this calcu-
lation, the expected frequency of TNBC cases without
family history among all breast cancers diagnosed
below the age of 50 years would be 26.1% (882
among 3376 cases), with an expected number of 149
pathogenic gBRCA mutation carriers (positive pre-
dictive value of 16.9% among TNBC cases under
50 years). The expected number of gBRCA carriers
among 2494 women with TNBC diagnosed at age 50
or above would amount to 109, corresponding to a
negative predictive value of 95.6%.
Discussion
We conducted the present study to determine up to
which age of TNBC diagnosis women without a family
history of breast and ovarian cancer should undergo
gBRCA testing if an expected mutation probability of at
least 10% is used as decision threshold. This cut-off is
currently used as general decision threshold to consider
gBRCA testing in Germany.
Our analysis of 802 women revealed that this age cut-
off lies at approximately 50 years. However, our analysis
also showed that the discriminative performance of age
at diagnosis as an exclusive predictor for the presence of
a gBRCA mutation was comparatively low with an
ROC-AUC of only 67%. If an age cut-off of 50 years
would be chosen, the sensitivity would be 97%, with a
specificity of 10%. If nationwide gBRCA mutation testing
in Germany would be offered to women with newly di-
agnosed TNBC before the age of 50 years, we expect to
identify around 150 additional mutation carriers among
around 880 women to be tested per year, corresponding
to a positive predictive value of approximately 17%.
Among the larger number of approximately 2500
women diagnosed with TNBC at 50 years or later, a total
of about 110 mutation carrying women would not be de-
tected (4.4%; negative predictive value 96.6%), which is
about 42% of all expected mutation carriers among
TNBC cases up to the age of 80 years.
A number of earlier studies have investigated the gBRCA
mutation prevalence in women with TNBC [13–22]. One
study based on 207 TNBC cases unselected for family
history has also employed logistic regression analysis to de-
scribe the association between age at diagnosis and muta-
tion probability accounting for the presence or absence of
family history [19]. In this study, the observed mutation
prevalence was 6.3% (95%CI 1–12%), which is lower than
found in our analysis. Couch et al. presented data on 1508
TNBC cases unselected for family history, for whom infor-
mation on age at diagnosis and family history was complete
[13]. In the subgroup of women with TNBC up to the age
Fig. 1 Association between age of TNBC diagnosis and gBRCA
mutation prevalence. Grey shaded bars indicate the mutation
prevalence in the according age group (error bars indicate 95%
confidence intervals). The bold curve represents the mutation
probability predicted by the logistic regression model (with 95%
confidence band, thin curves). The dashed horizontal line depicts
the 10% mutation probability, above which gBRCA mutation analysis
is recommended
Table 3 Expected annual number of women with TNBC and gBRCA mutation in Germany
Age group Number of newly
diagnosed BC
cases in 2012 a
% TNBC among
all BC cases b
% of TNBC
w/o FH c
Number of TNBC
cases w/o FH
% BRCA1/2 mutation
carriers among TNBC
cases w/o FH d
Number of BRCA1/2
mutation carriers among
TNBC cases without FH
< 40 2462 19.8 62.2 302 26.3 79
40–49 9757 10.5 56.8 580 12.1 70
50–59 15,059 9.0 65.8 891 6.9 61
60–69 16,497 7.0 71.9 835 3.8 32
70–79 15,420 6.9 71.9 768 2.1 16
FH family history, BC breast cancer, TNBC triple-negative breast cancer
aGerman Centre for Cancer Registry Data at the Robert Koch-Institute, Berlin, Germany
bMunich Cancer Registry, MCR, Munich, Germany
cCouch et al. [13]
dpresent study
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of 59 years without family history they reported a mutation
prevalence of 11.2% (BRCA1 8.1% and BRCA2 3.0%).
Current guidelines regarding the age up to which TNBC
patients should be offered gBRCA testing vary between
countries. The NICE guideline recommends gBRCA mu-
tation testing for women withTNBC and no family history
diagnosed before 40 years of age, while the NCCN guide-
line recommends testing up to the age of 60 years. The
normative definition of such decision thresholds depends
on the expected mutation probabilities above which insur-
ance carriers are willing to cover the costs for genetic test-
ing. However, the definition of optimal BRCA genetic
testing programs and decision cut-offs requires a thorough
economic evaluation regarding their cost-effectiveness
[23]. Such evaluations are currently not available for
Germany but urgently needed.
A limitation of our study is the comparatively low sam-
ple size for women with an age at TNBC diagnosis of
≥60 years, resulting in large confidence intervals of the
mutation prevalence estimates.
Conclusions
Based on the understanding that a heterozygous mutation
probability of ≥10% justifies gBRCA mutation screening,
women with triple-negative breast cancer diagnosed be-
fore the age of 50 years and no familial history of breast
and ovarian cancer should be tested for gBRCA muta-
tions. In Germany, this would concern approximately 880
women with newly diagnosed TNBC per year, of whom
approximately 150 are expected to be identified as patho-
genic gBRCA mutation carriers.
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